(Q48319736)

10 February 2018

title

Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. (English)

1 reference

10 February 2018

0 references

4

Hans-Peter Hartung

1 reference

10 February 2018

3

Bernd C Kieseier

1 reference

10 February 2018

Sebastian Jander

1

1 reference

10 February 2018

Bernd Turowski

series ordinal

2

1 reference

10 February 2018

publication date

1 November 2012

1 reference

10 February 2018

Multiple Sclerosis Journal

published in

1 reference

10 February 2018

volume

18

1 reference

10 February 2018

issue

11

1 reference

10 February 2018

page(s)

1650-1652

1 reference

10 February 2018

Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458512463768

Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512463768

Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512463768

Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512463768

Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512463768

21 January 2018

Identifiers

DOI

10.1177/1352458512463768

1 reference

10 February 2018

1 reference

10 February 2018